New injection aims to boost platelets in ITP patients
NCT ID NCT06929299
First seen Jun 26, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-phase trial tests a new drug called STSA-1301, given as an injection under the skin, for people with immune thrombocytopenia (ITP) — a condition where the immune system destroys platelets, raising bleeding risk. The study will first check safety in healthy volunteers, then test initial effectiveness in ITP patients. About 56 participants will receive either STSA-1301 or a placebo to see if it can safely raise platelet counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- STSA-1301 injection
- What this could lead to
- If it works, this could point toward a new treatment option for people with immune thrombocytopenia (ITP) to help raise low platelet counts.
- What could go wrong
- This is an early phase 1/2 trial with only 56 participants, so it is primarily testing safety. It may not show clear benefit, and side effects are unknown at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 475000, China
-
Hospital of Hematology, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300020, China
-
North China University of Science and Technology Affiliated Hospital
RECRUITINGTangshan, Hebei, 063000, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 101109, China
-
The First Affiliated Hospital of Bengbu Medical College
RECRUITINGBengbu, Anhui, 233000, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330000, China
-
Xi'an Central Hospital
RECRUITINGXi’an, Shanxi, 710000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for kids with ITP: drug combo aims to control bleeding
- New pill could help adults with low platelet disorder
- New drug combo aims to boost platelet counts in immune disorder
- New combo aims to boost platelets in stubborn ITP
- New hope for ITP patients: switching drugs after failed treatment
- New shot aims to boost platelets in ITP patients